Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the safety and tolerability of an investigational drug called elritercept, both alone and in combination with the JAK inhibitor ruxolitinib, in adults with myelofibrosis MF. The study also aims to understand how elritercept affects the signs and symptoms of MF, how the body processes the drug, and its effects on anemia when used with or without ruxolitinib. This is a Phase 2 open-label study focusing on participants with anemia related to MF.
Actively Recruiting
Researchers are evaluating the safety and effects of elritercept, a recombinant fusion protein, in treating anemia linked to lower-risk myelodysplastic syndromes MDS in adults. The study focuses on how well participants tolerate different doses of elritercept and its impact on anemia progression and healthy red blood cell production. This trial is a Phase 2, open-label study assessing elritercepts potential benefits for adults with very low, low, or intermediate risk MDS. Participants receive elritercept as a subcutaneous injection every 4 weeks on Day 1 of each 28-day cycle. Dose levels range from 0.75 mgkg to 5.0 mgkg, with treatment continuing for up to 24 cycles following an initial 4-cycle period. Dose adjustments may occur based on individual response. Special cohorts include participants with ring sideroblast-positive MDS, non-ring sideroblast MDS, chronic myelomonocytic leukemia with anemia, and those with iron overload or previous treatment with luspatercept. Some participants may continue treatment in a long-term extension phase lasting approximately 122 months. During the study, participants undergo regular monitoring for treatment-emergent adverse events and disease progression to higher-risk MDS or acute myeloid leukemia. Researchers assess red blood cell transfusion independence, hematologic improvement, erythropoietic response, hemoglobin changes, and red cell parameters over the treatment period, which may last up to 11.2 years. The study includes evaluations of safety, efficacy, and long-term effects of elritercept, with ongoing follow-up visits and assessments to track participants health and response to treatment.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating ways to improve hepatitis C virus HCV care in drug treatment clinics and needle and syringe programs in New South Wales and across Australia. The ETHOS II Project aims to develop a framework to establish HCV screening and treatment programs in these settings nationally. This collaborative research involves several health organizations and focuses on people with a history of injecting drug use or those receiving opioid substitution therapy. The study includes an intervention called campaign days where participants receive hepatitis C screening, liver fibrosis assessments using fibroscans, and clinical assessments. Participants also complete surveys and may consent to link their data with population databases. A sub-study involves collecting blood samples from some participants to evaluate new diagnostic tests for chronic HCV infection. Additionally, interviews with policymakers, clinicians, and patients will explore barriers to HCV care, and an education program will be developed to improve workforce knowledge and care quality. Participants will be recruited from drug treatment clinics, general practitioners with high case loads, and needle and syringe programs. They will undergo hepatitis C testing, fibroscans, clinical assessments, and complete questionnaires during the campaign days. Researchers will track how many participants start anti-HCV treatment each year for up to three years. The study also includes follow-up through medical record reviews to monitor outcomes and improve treatment access and delivery.
Actively Recruiting
Researchers are studying metastatic pancreatic ductal adenocarcinoma PDA in adults who have not been previously treated for this condition. The trial evaluates the effect of adding SBP-101, a small molecule polyamine metabolic inhibitor, to the standard chemotherapy regimen of gemcitabine and nab-paclitaxel. This randomized, double-blind, placebo-controlled, multicenter study aims to assess overall survival and other important outcomes in about 600 patients. Participants will receive either SBP-101 combined with nab-paclitaxel and gemcitabine or a placebo with the same chemotherapy drugs. The treatments are given as injections, and the study includes two groups one experimental arm receiving SBP-101 plus chemotherapy and one control arm receiving placebo plus chemotherapy. The safety and effectiveness of treatments will be monitored throughout the trial by an independent committee. During the study, patients will be followed for overall survival up to 100 weeks or until death. Researchers will also measure progression-free survival, responses seen on scans, and quality of life. Assessments include imaging with CT or MRI, blood tests, and monitoring of side effects. Participants must consent to the study and meet specific health criteria, and safety will be closely observed throughout the trial period.